Pioneering and advancing treatments for severe inflammation and autoimmune diseases by selectively targeting shared critical pathways driving disease pathogenesis. Lead program, Inebilizumab, is a CD19 mAb currently in Phase 2b for the treatment of Neuromyelitis Optica. Full global rights to 6 assets (4 clinical, 2 preclinical) from AstraZeneca/Medimmune.
One MedImmune Way
Fifth Floor, Suite Area Two
Gaithersburg, MD 20878
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.